Sexual Rehabilitation After Therapy for Localized Disease
Sexual rehabilitation is not a process that begins only after treatment for localized prostate cancer. Men and their partners need some understanding of the sexual consequences of cancer treatment in order to make an informed choice about cancer therapy. Not only have such organizations as the American Cancer Society, the National Prostate Cancer Coalition, and the American Foundation for Urological Diseases worked to increase the public’s knowledge about prostate cancer and recommendations for screening, but they also have encouraged men to participate actively in decision making about their cancer treatment. Compared to just 10 years ago, men now have dozens of books, internet websites, and pamphlets available giving advice on choosing an effective treatment and avoiding complications, such as sexual dysfunction. Many men are aware of publicity about the limited data showing effectiveness of aggressive treatment for prostate cancer, and the advocacy by some physician groups of reduced use of screening and increased use of watchful waiting as a treatment option (1).
KeywordsProstate Cancer Erectile Dysfunction Radical Prostatectomy Sexual Function Sexual Dysfunction
Unable to display preview. Download preview PDF.
- 1.Coley CM, Barry MJ, Mulley AG, for the Health and Public Policy Committee of the American College of Physician. Position paper: clinical guidline: Part III: Screening for prostate cancer. Ann Int Med 1997; 126: 480–484.Google Scholar
- 29.Schover LR. Sexuality and Fertility After Cancer. John Wiley, New York, 1997.Google Scholar
- 31.Schover LR. Sexuality and Cancer: For the Man Who Has Cancer and His Partner. American Cancer Society, New York, (booklet 4658), rev., 1995.Google Scholar
- 32.Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997; 158: 1408–1410.PubMedCrossRefGoogle Scholar
- 34.Zorgniotti AW, LeFleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985; 133: 339–341.Google Scholar
- 36.Padma-Nathan H. Minimally invasive therapy for erectile dysfunction: intracavernosal, oral, transdermal/transglanular and intraurethral approaches. In: Mulcahy JJ, ed. Diagnosis and Management of Male Sexual Dysfunction. Igaku-Shoin, New York, 1997, pp. 182–195.Google Scholar
- 39.Lakin MM, Montague DK. Non-surgical therapeutic alternatives for impotence. In: Hashmat Aizid I, Das S, eds. The Penis. Lea and Febiger, Philadelphia, 1993, pp. 154–173.Google Scholar
- 46.Costabile RA, Govier FE, Ferrigni RG, McVary KT, Shabsigh R, Nemo KJ, et al. Safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1997; 157 (4): 1424.Google Scholar
- 47.Paolone DR, Lakin MM, Ingleright BJ, Angermeier KW, Montague DK. Intraurethral Alprostadil Therapy at The Cleveland Clinic Foundation. Abstract submitted to North Central Section AUA for presentation in October, 1998.Google Scholar
- 49.Schover LR, Montague DK, Lakin MM. Supportive care and the quality of life of the cancer patient: sexual problems. In: Cancer: Principles and Practice of Oncology, 5th ed. De Vita JT, Hellman S, Rosenberg SA, eds. Lippincott, Philadelphia, 1997, pp. 2857–2872.Google Scholar